Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors

AIDS

Volumn 32, Issue 4, 2018, Pages 443-450

  Sadanand, Saheli ^a   Das, Jishnu ^a,e   Chung, Amy W ^a,b   Schoen, Matthew K ^a   Lane, Sophie ^a   Suscovich, Todd J ^a   Streeck, Hendrik ^c   Smith, Davey M ^d   Little, Susan J ^d   Lauffenburger, Douglas A ^e   Richman, Douglas D ^f,g   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute HIV; antibody dependent effector functions; controllers; HIV specific IgG; IgG subclasses; IgG2; IgG3; progressors

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLADISTICS; DISEASE EXACERBATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PHAGOCYTOSIS; PRIORITY JOURNAL; VIREMIA; VIRUS INHIBITION; BLOOD; CELLULAR IMMUNITY; CLASSIFICATION; COHORT ANALYSIS; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; IMMUNOLOGY; PATHOLOGY;

COHORT STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; EARLY DIAGNOSIS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G;

EID: 85042458822     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001716     Document Type: Article

References (41)

1. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
2. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999; 180:1338-1341.
3. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157:2168-2173.
4. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIVinfected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18:1197-1205.
5. Ohkawa S, Wilson LA, Larosa G, Javaherian K, Martin LN, Murphey-Corb M. Immune responses induced by prototype vaccines for AIDS in rhesus monkeys. AIDS Res Hum Retroviruses 1994; 10:27-38.
6. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011; 58:127-131.
7. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 2013; 155:531-539.
8. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158:1243-1253.
9. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
10. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-Titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
11. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5:520.
12. Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 2011; 25:2099-2104.
13. Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, et al. Independent evolution of Fc-And Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 2014; 44:2925-2937.
14. Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 2011; 25:2089-2097.
15. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009; 182:3718-3727.
16. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicitymediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177: 4028-4036.
17. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75: 6953-6961.
18. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571.
19. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9:55-69.
20. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 2011; 24:359-368.
21. Lai JI, Licht AF, Dugast AS, Suscovich T, Choi I, Bailey-Kellogg C, et al. Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J Virol 2014; 88:2799-2809.
22. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
23. Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One 2013; 8:e74855.
24. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, et al. Breadth of HIV-1 Env-specific antibodydependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS 2014; 28:1859-1870.
25. Ackerman ME, Dugast AS, McAndrew EG, Tsoukas S, Licht AF, Irvine DJ, Alter G. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgR2a and FcgR2b. J Virol 2013; 87:5468-5476.
26. Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog 2016; 12:e1005315.
27. Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4R T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218-230.
28. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416.
29. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME. High-Throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods 2012; 386:117-123.
30. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-Throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011; 366:8-19.
31. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014; 6:228ra238.
32. Asmal M, Sun Y, Lane S, Yeh W, Schmidt SD, Mascola JR, Letvin NL. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesusmonkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol 2011; 85:5465-5475.
33. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B 1996; 58:267-288.
34. Chung AW, Kumar MP, Arnold KB, YuWH, SchoenMK, Dunphy LJ, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIVusing systems serology. Cell 2015; 163:988-998.
35. Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, Turnbaugh PJ, et al. Detecting novel associations in large data sets. Science 2011; 334:1518-1524.
36. Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, et al. Nonneutralizing antibodies alter the course of HIV-1 infection in vivo. Cell 2017; 170:637-648.e610.
37. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014; 6:228ra239.
38. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11:836-845.
39. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3:822-829.
40. Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006; 355:1-5.
41. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, et al. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 2011; 30:78-94.